The Monoclonal Antibody treatment can block the SARS-CoV-2 virus (the virus that causes COVID-19) from entering cells in your body and limit the amount of the virus within your body. This means you may have milder symptoms and may decrease the likelihood of you needing to stay in the hospital.
If you are at risk for serious COVID-19 and you have tested positive for COVID-19 or have been in close contact with someone who has tested positive, you may want to consider a monoclonal antibody (mAb) treatment. You may qualify for this promising COVID-19 treatment depending on your age, health history, and how long you have had symptoms. You do not need to have symptoms or test positive to qualify for mAb treatment if you are at high risk for serious COVID-19.
The mAb treatment may help people who:
Visit the page Who is at high risk for serious COVID-19? to learn more.
As the United States and world continue to fight the COVID-19 pandemic, America’s biopharmaceutical research companies continue to do our part in fighting this deadly virus. Decades of scientific innovation have allowed biopharmaceutical researchers to respond quickly and continue to research and develop treatments and vaccines for COVID-19. Importantly, the best strategy to prevent infection against COVID-19 is to get vaccinated. Three vaccines are currently available for protection against COVID-19, one of which was recently approved by The U.S. Food and Drug Administration (FDA) for use in certain populations. These vaccines are safe and have been administered to over a hundred million Americans, and billions around the world. To date, one antiviral is also currently approved by the FDA for use in patients 12 years of age and older for the treatment of COVID-19, which has the ability to speed recovery time by up to 5 days.